Summary
A prototype Bovine Respiratory Disease (BRD) vaccine for two viral agents Bovine herpesvirus 1 and Bovine viral diarrhoea virus was constructed and its safety and efficacy evaluated in pen trials. The prototype vaccine was safe as no adverse reactions were observed in any of the 64 cattle vaccinated throughout the study.
Efficacy data from challenge trials demonstrated the prototype vaccine provided similar protection to one currently registered vaccine. The prototype vaccine now requires a commercialisation partner to deliver the vaccine to industry in order to provide further options to reduce the impact of BRD on the Australian feedlot sector.
